z-logo
open-access-imgOpen Access
The bone tissue compatibility of a new Ti35Nb2Ta3Zr alloy with a low Young’s modulus
Author(s) -
Yongyuan Guo,
Desheng Chen,
Mengqi Cheng,
Wei Lu,
Liqiang Wang,
Xianlong Zhang
Publication year - 2013
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2013.1249
Subject(s) - biocompatibility , materials science , osteopontin , titanium alloy , osteocalcin , alloy , elastic modulus , bone tissue , osteoblast , biomedical engineering , alkaline phosphatase , metallurgy , composite material , in vitro , chemistry , medicine , biochemistry , enzyme
Titanium (Ti) alloys of the β-type are highly attractive metallic materialsfor biomedical applications due to their low elastic modulus, high corrosion resistanceand notable biocompatibility. A new β-type Ti35Nb2Ta3Zr alloy with a low Young'smodulus of approximately 48 GPa was previously fabricated. In the present study,the biocompatibility of this alloy was evaluated. In an in vitro assay, the Ti35Nb2Ta3Zralloy did not markedly affect the adhesion of MG63 osteoblast cells, but it increasedtheir proliferation, alkaline phosphatase (ALP) activity, calcium deposition andmRNA expression of osteogenic genes (i.e., ALP, osteocalcin, osteopontin). Inan in vivo study, no marked histological differences were observed between thenew bone formed on the surface of Ti35Nb2Ta3Zr and that formed on the surfaceof control Ti6Al4V rods placed in the medullary canal of rabbit femurs. Additionally,no significant differences were observed in the failure load of Ti35Nb2Ta3Zr andTi6Al4V in pull-out tests. In conclusion, the Ti35Nb2Ta3Zr alloy with a lowerelastic modulus closer to that of human bone has significant bone tissue compatibilityequal to that of Ti6Al4V, which has been widely used in orthopedic applications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here